StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3057% below fair value
$0.41−0.03 (-7.45%)

Close on Nov 20, 2026Market cap $121.65MP/E –Yield –

Invivyd free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Invivyd's free cash flow for the twelve months ending Jun 30, 2026 was -$109.66M. For fiscal 2025 it was -$58.29M. The highest annual figure on record is -$58.29M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.29M–
FY2024Dec 31, 2024-$170.63M–
FY2023Dec 31, 2023-$173.78M–
FY2022Dec 31, 2022-$221.69M–
FY2021Dec 31, 2021-$184.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$43.52M–
Q1 FY2026Mar 31, 2026-$42.44M–
Q4 FY2025Dec 31, 2025-$15.46M–
Q3 FY2025Sep 30, 2025-$8.25M–
Q2 FY2025Jun 30, 2025-$13.31M–
Q1 FY2025Mar 31, 2025-$21.27M–
Q4 FY2024Dec 31, 2024-$37.61M–
Q3 FY2024Sep 30, 2024-$41.07M–
Q2 FY2024Jun 30, 2024-$41.60M–
Q1 FY2024Mar 31, 2024-$50.35M–
Q4 FY2023Dec 31, 2023-$59.24M–
Q3 FY2023Sep 30, 2023-$35.35M–
Q2 FY2023Jun 30, 2023-$37.38M–
Q1 FY2023Mar 31, 2023-$41.81M–
Q4 FY2022Dec 31, 2022-$48.62M–
Q3 FY2022Sep 30, 2022-$56.62M–
Q2 FY2022Jun 30, 2022-$57.41M–
Q1 FY2022Mar 31, 2022-$59.05M–
Q4 FY2021Dec 31, 2021-$73.30M–
Q3 FY2021Sep 30, 2021-$54.21M–

More Invivyd figures

See a number that looks wrong?